Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study - 2012 - 2015

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{ca08aa938f074187b6257d04935dac27,
title = "Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study - 2012 - 2015",
abstract = "BACKGROUND: It is cost-effective to perform an HIV test in people with specific indicator conditions (IC) with an undiagnosed HIV prevalence of at least 0.1{\%}. Our aim was to determine the HIV prevalence for 14 different conditions across 20 European countries.METHODS: Individuals aged 18-65 years presenting for care with one of 14 ICs between January 2012 and June 2014 were included and routinely offered an HIV test. Logistic regression assessed factors associated with testing HIV positive. Patients presenting with infectious mononucleosis-like syndrome (IMS) were recruited up until September 2015.RESULTS: Of 10,877 patients presenting with an IC and included in the analysis, 303 tested positive (2.8{\%}; 95{\%} CI 2.5-3.1{\%}). People presenting with an IC in Southern and Eastern Europe were more likely to test HIV positive as were people presenting with IMS, lymphadenopathy and leukocytopenia/ thrombocytopenia. One third of people diagnosed with HIV after presenting with IMS reported a negative HIV test in the preceding 12 months. Of patients newly diagnosed with HIV where data was available, 92.6{\%} were promptly linked to care; of these 10.4{\%} were reported lost to follow up or dead 12 months after diagnosis.CONCLUSION: The study showed that 10 conditions had HIV prevalences > 0.1{\%}. These 10 ICs should be adopted into HIV testing and IC specialty guidelines. As IMS presentation can mimic acute HIV sero-conversion and has the highest positivity rate, this IC in particular affords opportunities for earlier diagnosis and public health benefit.",
author = "{HIDES Study Group} and Dorthe Raben and Sullivan, {Ann Kathleen} and Amanda Mocroft and Galyna Kutsyna and Vesna Hadžiosmanović and Anna Vassilenko and Nikoloz Chkhartisvili and Viktar Mitsura and Court Pedersen and Jane Anderson and Josip Begovac and {Bak Dragsted}, Ulrik and Barbara Bertisch and Anna Grzeszczuk and Jane Minton and Necsoi, {Valentina Coca} and Maria Kitchen and Faiza Ajana and Anton Sokhan and Laura Comi and Paymaneh Farazmand and Dragica Pesut and {De Wit}, Stephane and Gatell, {Jos{\'e} Maria} and Brian Gazzard and {d'Arminio Monforte}, Antonella and Rockstroh, {J{\"u}rgen Kurt} and Yazdan Yazdanpanah and Karen Champenois and Jakobsen, {Marie Louise} and Lundgren, {Jens Dilling}",
year = "2019",
doi = "10.1371/journal.pone.0220108",
language = "English",
volume = "14",
pages = "e0220108",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

RIS

TY - JOUR

T1 - Improving the evidence for indicator condition guided HIV testing in Europe

T2 - Results from the HIDES II Study - 2012 - 2015

AU - HIDES Study Group

AU - Raben, Dorthe

AU - Sullivan, Ann Kathleen

AU - Mocroft, Amanda

AU - Kutsyna, Galyna

AU - Hadžiosmanović, Vesna

AU - Vassilenko, Anna

AU - Chkhartisvili, Nikoloz

AU - Mitsura, Viktar

AU - Pedersen, Court

AU - Anderson, Jane

AU - Begovac, Josip

AU - Bak Dragsted, Ulrik

AU - Bertisch, Barbara

AU - Grzeszczuk, Anna

AU - Minton, Jane

AU - Necsoi, Valentina Coca

AU - Kitchen, Maria

AU - Ajana, Faiza

AU - Sokhan, Anton

AU - Comi, Laura

AU - Farazmand, Paymaneh

AU - Pesut, Dragica

AU - De Wit, Stephane

AU - Gatell, José Maria

AU - Gazzard, Brian

AU - d'Arminio Monforte, Antonella

AU - Rockstroh, Jürgen Kurt

AU - Yazdanpanah, Yazdan

AU - Champenois, Karen

AU - Jakobsen, Marie Louise

AU - Lundgren, Jens Dilling

PY - 2019

Y1 - 2019

N2 - BACKGROUND: It is cost-effective to perform an HIV test in people with specific indicator conditions (IC) with an undiagnosed HIV prevalence of at least 0.1%. Our aim was to determine the HIV prevalence for 14 different conditions across 20 European countries.METHODS: Individuals aged 18-65 years presenting for care with one of 14 ICs between January 2012 and June 2014 were included and routinely offered an HIV test. Logistic regression assessed factors associated with testing HIV positive. Patients presenting with infectious mononucleosis-like syndrome (IMS) were recruited up until September 2015.RESULTS: Of 10,877 patients presenting with an IC and included in the analysis, 303 tested positive (2.8%; 95% CI 2.5-3.1%). People presenting with an IC in Southern and Eastern Europe were more likely to test HIV positive as were people presenting with IMS, lymphadenopathy and leukocytopenia/ thrombocytopenia. One third of people diagnosed with HIV after presenting with IMS reported a negative HIV test in the preceding 12 months. Of patients newly diagnosed with HIV where data was available, 92.6% were promptly linked to care; of these 10.4% were reported lost to follow up or dead 12 months after diagnosis.CONCLUSION: The study showed that 10 conditions had HIV prevalences > 0.1%. These 10 ICs should be adopted into HIV testing and IC specialty guidelines. As IMS presentation can mimic acute HIV sero-conversion and has the highest positivity rate, this IC in particular affords opportunities for earlier diagnosis and public health benefit.

AB - BACKGROUND: It is cost-effective to perform an HIV test in people with specific indicator conditions (IC) with an undiagnosed HIV prevalence of at least 0.1%. Our aim was to determine the HIV prevalence for 14 different conditions across 20 European countries.METHODS: Individuals aged 18-65 years presenting for care with one of 14 ICs between January 2012 and June 2014 were included and routinely offered an HIV test. Logistic regression assessed factors associated with testing HIV positive. Patients presenting with infectious mononucleosis-like syndrome (IMS) were recruited up until September 2015.RESULTS: Of 10,877 patients presenting with an IC and included in the analysis, 303 tested positive (2.8%; 95% CI 2.5-3.1%). People presenting with an IC in Southern and Eastern Europe were more likely to test HIV positive as were people presenting with IMS, lymphadenopathy and leukocytopenia/ thrombocytopenia. One third of people diagnosed with HIV after presenting with IMS reported a negative HIV test in the preceding 12 months. Of patients newly diagnosed with HIV where data was available, 92.6% were promptly linked to care; of these 10.4% were reported lost to follow up or dead 12 months after diagnosis.CONCLUSION: The study showed that 10 conditions had HIV prevalences > 0.1%. These 10 ICs should be adopted into HIV testing and IC specialty guidelines. As IMS presentation can mimic acute HIV sero-conversion and has the highest positivity rate, this IC in particular affords opportunities for earlier diagnosis and public health benefit.

U2 - 10.1371/journal.pone.0220108

DO - 10.1371/journal.pone.0220108

M3 - Journal article

VL - 14

SP - e0220108

JO - P L o S One

JF - P L o S One

SN - 1932-6203

IS - 8

ER -

ID: 57878307